The United States Supreme Court is set to make a pivotal decision on access to the abortion pill in a case that could have far-reaching implications.
The justices took up the administration’s appeal of an August decision by the New Orleans-based 5th U.S. Circuit Court of Appeals that would curb how the pill, called mifepristone, is delivered and distributed, barring telemedicine prescriptions and shipments by mail of the drug. The high court also agreed to hear an appeal by the drug’s manufacturer, Danco Laboratories.
Proponents of the law argue that it safeguards women’s health by ensuring they receive the medication under proper medical supervision. However, critics claim it places undue burdens on women seeking abortion care, especially those living in rural or underserved areas.
This case has garnered nationwide attention, with reproductive rights activists and pro-choice advocates closely watching the proceedings.
The Supreme Court’s decision could either bolster or undermine the landmark 1973 Roe v. Wade ruling, which established the constitutional right to abortion in the US.
